Roche Takes Back Evotec's EVT-302 To Develop In Alzheimer's Disease, In $800 Million Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Evotec and Roche are to collaborate on the development of the MAO-B inhibitor, EVT-302, for Alzheimer's disease, a compound that previously failed in another indication, as an aid to smoking cessation.
You may also be interested in...
Evotec Drug Development Strategy Offers Little Downside, Big Upside
Germany’s Evotec hopes to evolve into an integrated multi-service biopharma company through its three-pronged business strategy comprising a high-growth drug-discovery business, a series of pipeline options that pose no financial obligation for the biotech, and a growing list of scientific collaborations that offer potential long-term value.
Beyond A-Beta: New Approaches To Alzheimer’s
The Alzheimer’s Association International Conference is under way in Vancouver through July 19, but some of the most anticipated news regarding drug development for the disease is likely to take place later this year. There’s plenty of hope, but not much optimism that pivotal trials for bapneuzumab and solanezumab will succeed. Regardless of the outcome, the results will have an impact on which approaches to Alzheimer’s come next—and how they get funded.
Beyond A-Beta: New Approaches To Alzheimer’s
The track record for anti-amyloid beta Alzheimer’s treatments has been dismal. If upcoming results from pivotal trials for bapineuzumab and solanezumab are disappointing, they won’t scuttle the approach completely, but much more attention would shift toward other targets. We highlight two targets that have gained more attention of late, extracellular tau and ApoE4, and a diverse group of scientists working to move their work forward.